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In general, a very informative manuscript with generalizable findings on a topic with important health policy implications. Suggestions for strengthening the manuscript are below.
Major Issues:
1)
In several places in the manuscript (including the abstract) you imply or directly compare the HZ IR among the IC conditions. However, due to the vastly different age structure of these populations, they are not directly comparable. I suggest age standardization as the best mechanism to allow a direct comparison. Comparison of IRR of IC vs IC-free for each of the conditions would be less rigorous but still informative.
2)
Your STROBE checklist indicates Bias N/A-this is a serious oversight and should be addressed. Chronic conditions are usually a marker for increased physician visits and care-seeking. This may increase the likelihood of HZ episode presenting for medical attention. Moreover, PHN is a notoriously bias-prone administrativerecord diagnosis and may be sensitive to the effect of care seeking.
Introduction
Line 87 "large contribution to the societal healthcare burden" this is not adequately referenced. Line 88-as PHN rarely requires hospitalization I would be more explicit about the impact of HZ and PHN in the IC individual. Is the VZV related disease more severe? May VZV related disease exacerbate the IC condition? In what ways? Line 91-suggest replacing "burden" with incidence.
Methods Line 108-presumably the read codes coded diagnosis? For those not familiar please spell it out if they are used in lieu of ICD codes etc. Line 111-4.4 million individuals registered with 674 GP practices. That is 6528 patients per GP. Is that a regular roster over this study period? Seems like a lot. 119-how was "active" defined? 120-Did all study subjects have HES linkage? Was this an inclusion criterion? 121-what does 1 year follow-up mean? 122-132-this is a very complex series of case definitions and would benefit from a table published with the manuscript-details such as how CORTDS is defined need to be easily accessible. 133-index date-was the earliest date possible Jan 1 2000? Please be explicit. 161-if IC subjects were censored on 1st HZ episode, how were they followed for the development of PHN, complications or recurrence? 170-Do you mean that recurrent zoster was calculated as recurrent HZ event 6 months-24 months following the incident event? Since the median f/up was much longer, why did you decide on the 2 yr cut-off?
Results -17% of the study population is IC? Although this is not an area with good estimates, this seems very high. I suggest addressing this in the discussion 185-give the range as well as mean, please. Table 1 -I suggest adding a column which depicts the study population so the reader can see in what ways the IC group differs from the population on these demographic points -Why is the follow-up time shorter for the IC-free cohort? I would have expected all the censoring events to be more common in the IC group. 194-Is (6.12-6.30) a 95% CI? Table 2-this is a very informative table. Consider adding the number of subjects in each cell. This will give the reader a better sense of the different age distribution of the various IC conditions. 208-"The IRs of HZ for each IC condition rose steadily with increasing age (Table 2) ." I don't think this observation is true. For example, HSCT risk jumps after age 50 and stays high with fluctuations, presumably because of low power. Solid organ, similarly, is not significantly different between 50-59 through >80. Discussion 271-this may be true overall but as you have not shown the calendar time analysis for each IC group, this may not be true for each group. There are many confounders such as the development of new medication regimes over the study period which may influence 279-the inclusion of pain medication as the case definition for PHN generally increases specificity and decreases sensitivity-therefore one would expect the rates to be lower in the studies you cite. 314-these risk factors with low OR need to interpreted with extreme caution. The diagnosed chronic conditions may indicate increased physician visits and care-seeking. PHN is a notoriously bias-prone administrative-record diagnosis and may be sensitive to these factors. I suggest doing a sensitivity analysis to frequency of physician visits and control for them if you think this factor could introduce bias. 329-334-This point is very difficult to follow. I suggest re-writing for clarity. 335-338-I suggest expanding this section to discuss the timevariability of many of the IC conditions (eg. CORT) which was only crudely accounted for in your analysis. 350-352-very vague concluding sentence. Obviously, the most important new preventive tool on the horizon is the recombinant vaccine-I suggest you conclude with implications for vaccination. 
REVIEWER

GENERAL COMMENTS
On the strengths of the paper, the major strength was not clearly outlined, as it concerns its advantage over previous studies, either in the area of new or better methodologies and so on, That this study covered more populations than previous studies is not strong enough reason. Also, the limitation of the study is too shallow, not explicit enough.
VERSION 1 -AUTHOR RESPONSE
Reviewer In general, a very informative manuscript with generalizable findings on a topic with important health policy implications. Suggestions for strengthening the manuscript are below.
1)
In several places in the manuscript (including the abstract) you imply or directly compare the HZ IR among the IC conditions. However, due to the vastly different age structure of these populations, they are not directly comparable. I suggest age standardization as the best mechanism to allow a direct comparison. Comparison of IRR of IC vs IC-free for each of the conditions would be less rigorous but still informative. We acknowledge that some of selected IC conditions are more common in younger versus older age groups, and direct comparison between specific IC and IC-free would be interesting but it will require formal statistical models adjusting for a diversity of co-variates.
Regarding the comparison between different IC groups, the study is a descriptive one and its primary objective is to describe the overall IR of HZ as well as its rate stratified by age and gender in each IC condition. We were concerned about the potential heterogeneity of IC populations that would not allow us to have a robust statistical comparison between IC groups because of the small number of patients included in some of the selected IC groups in the health care records of the GPs and hospital discharge summaries.
Although it would be interesting to compare IC versus IC-free using the IRR for each of the IC conditions, we will not be able to conduct that statistical analysis as part of the submitted paper because it is beyond the scope of the current descriptive study protocol that was approved by ISAC for the use of CPRD and HES datasets.
However, to minimize the potential bias associated with a very different IC population from the IC-free and to allow for an informative descriptive analysis, we matched the IC and IC free population by age, gender and clinic practice geographic region to ensure that they had similar pattern of diagnoses, treatment and recording practices. The study total cohort, and IC and IC-free matched cohorts have HES linkages.
2)
Your STROBE checklist indicates Bias N/A-this is a serious oversight and should be addressed. Chronic conditions are usually a marker for increased physician visits and care-seeking. This may increase the likelihood of HZ episode presenting for medical attention. Moreover, PHN is a notoriously bias-prone administrative-record diagnosis and may be sensitive to the effect of care seeking. Apart from age, none of the factors in the model are strongly associated with PHN in IC and the small aOR should be interpreted with extreme caution. We agree with your comment that chronic diseases are markers for increased physician visits and care-seeking behavior. We updated the STROBE checklist and addressed your comment in the limitations section in page 25 (Line 376-380). We also acknowledge that the PHN has a potential ascertainment bias when the diagnosis is abstracted from administrative health records. However, the CPRD is an electronic health record of GP practices, and therefore it is less liable for ascertainment bias in comparison to the medical claim administrative records. In addition, we restricted the identification of PHN cases to the Read code and ICD-10 codes of PHN.
Regarding the aOR of PHN risk factors model, we addressed your comment in the paper (Line 347-349, page 24).
3)
Need more detail regarding how the IC conditions were defined. The current definitions make it difficult to understand the paper and limit reproducibility. A table detailing the diagnostic codes is a first step. As described in the methods section, each IC disease was defined by diagnosis code of the IC disease by using ICD-10 in HES or corresponding Read codes in CPRD, and/or medical procedure by using ICD-10 codes in HES.
As the list of Read codes and ICD-10 codes used to define the IC diseases is quite long (more than 150 pages) and the related algorithms are quite complex, we added a brief summary in the supplementary materials that focus on corticosteroids and immunosuppressant medicine. We will be willing to provide detailed list of codes that describe the IC conditions upon request.
More detail is needed on how you dealt with time-varying IC from immunosuppressive medications. For example, would a pt who received a highdose pulse of steroids for an allergic reaction remain in the CORTDS group for the remainder of the study period? The section we added to the supplementary material is summarizing the time exposure to corticosteroids and immunosuppressant medication For instance, a patient who received high dose of corticosteroids will be considered at risk for HZ for 3 months after the last prescription and for 6 months after the last prescription of other immunosuppressant medication. He/she will not remain in the study for the remainder of the study period.
Introduction
Line 87 "large contribution to the societal healthcare burden" this is not adequately referenced. We added three more references to the paper that show the risk of severe HZ complications and hospitalization in IC populations. The data used for this study was not detailed enough to stratify the IC condition accurately by its severity. For instance, the available HES-linked CPRD data provides the hospital discharge diagnoses that include the HZ complication diagnosis code with or without a diagnosis code for the IC condition, but not the level of severity of IC condition. Assessing the severity would require the development of algorithms that combine the IC condition codes and dose and duration of prescribed medications.
Line 91-suggest replacing "burden" with incidence. The wording was updated accordingly.
Methods
Line 108-presumably the read codes coded diagnosis? For those not familiar please spell it out if they are used in lieu of ICD codes etc. We added an explanation to the methods section. Read diagnostic terms are a set of clinical descriptions that GP primary care practices use to manage the data in patients' electronic records. They are named after Dr James Read, the initial author of the terms list adopted by NHS in 1985.
Line 111-4.4 million individuals registered with 674 GP practices. That is 6528 patients per GP. Is that a regular roster over this study period? Seems like a lot. This average number is close to that mentioned in the NHS reports but kindly notice that the count refers to GP clinic practices that might include one or many GPs per practice. We checked the NHS website and the number of patients per practices range from 200 up to 10,000, therefore the study population distribution is within the expected range.
119-how was "active" defined? Patients in England are registered to one GP practice, the GP functions as the NHS gate keeper for the provided health care. An active patient is defined as a subject with a valid registration in a GP practices (not a temporary registration as for example, migrant workers or homeless individuals).
Active also requires that subjects have not been transferred out of the practice (e.g. moving to another city , death or admission to institutionalized care, or prison). In addition, they had contact with their general practice during any time from one year before to two years after the index date. 120-Did all study subjects have HES linkage? Was this an inclusion criterion? Yes, HES linkage was one of the study inclusion criteria in order to be able to analyze the hospital admission data.
121-what does 1 year follow-up mean? It means that study population who were included in the study between Jan. 1st, 2000 and March 31, 2012 had a follow-up in the HES-CPRD database for at least 365 days before the inclusion date to make sure that they did not have any previous incident of HZ.
122-132-this is a very complex series of case definitions and would benefit from a table published with the manuscript-details such as how CORTDS is defined need to be easily accessible. As described in the methods section, each IC disease was defined by diagnosis code of the IC disease by using ICD-10 in HES or corresponding Read codes in CPRD, and/or medical procedure by using ICD-10 codes in HES. As the list of Read codes and ICD-10 codes used to define the IC diseases is quite long (more than 150 pages) and the related algorithms quite complex, we added a brief summary in the supplementary materials that cover corticosteroids and OIT. We will be willing to provide detailed list of codes that describe the IC conditions upon request.
133-index date-was the earliest date possible Jan 1 2000? Please be explicit. We added the date.
161-if IC subjects were censored on 1st HZ episode, how were they followed for the development of PHN, complications or recurrence? For the purpose of calculating the HZ incidence rate , the denominator, i.e. person-time at risk, of IC subjects were censored on 1st HZ episode. However, for the purpose of the calculation of the proportion of cases with HZ complications, we followed the patients until the end of the follow up in the study.
170-Do you mean that recurrent zoster was calculated as recurrent HZ event 6 months-24 months following the incident event? Since the median f/up was much longer, why did you decide on the 2 yr cut-off? It was an arbitrary decision by the study team to limit the follow up of recurrent HZ event to 6 months to 24 months after the HZ incident. The decision was based on few previous researches using the same 2-year follow up period, so we could easily compare our study results to other studies that reported recurrent HZ rate within two years such as Kawai K et al, 2014. Results -17% of the study population is IC? Although this is not an area with good estimates, this seems very high. I suggest addressing this in the discussion We added a paragraph in page 24 (line 355-359) to address that issue, but we will discuss in details and put into context the IC population demographics used in the analyses in a complementary methods paper that is currently under development.
185-give the range as well as mean, please. Given the nature of the real-world clinical data, ranges were extremely wide and uninformative. We did not included ranges for any of the descriptive results in the tables and would prefer not to include them given their lack of information value and increased complexity of the table.
Table 1-I suggest adding a column which depicts the study population so the reader can see in what ways the IC group differs from the population on these demographic points The study population table SM3 includes the demographic characteristics of all study participants at the date of inclusion in the study which is different from the variables of Table 1 that show the age of subjects at the index date . To avoid any confusion for the readers, we added a supplementary Table  3 to the supplementary materials that shows the demographic characteristics of study population.
-Why is the follow-up time shorter for the IC-free cohort? I would have expected all the censoring events to be more common in the IC group. The follow up time extends from the index date to the end of follow-up in the study (line 154-156) for the matched IC and IC-free population. There was no censoring events per say, but we used it only when we calculated the IR of HZ per person-year and then HZ patients were followed until the end of study follow up.
The mean number of years of follow up from the index date to the end of eligibility in IC free (4.9 years) is very close to that of IC population (5.1 years). We do not have an explanation but it is possible that the IC-free population are moving more frequently to other geographic locations especially if they were younger.
194 Is (6.12-6.30) a 95% CI? Yes, we added them Table 2 is very informative table. Consider adding the number of subjects in each cell. This will give the reader a better sense of the different age distribution of the various IC conditions. Table 2 : We tried to add the number of subjects in each cell but the table became very crowded and it was difficult to be read.
208-"The IRs of HZ for each IC condition rose steadily with increasing age (Table 2) ." I don't think this observation is true. For example, HSCT risk jumps after age 50 and stays high with fluctuations, presumably because of low power. Solid organ, similarly, is not significantly different between 50-59 through >80. We agreed with your comment and we changed the sentence to ". The IRs of HZ for each IC condition rose steadily with increasing age except for HSCT, HM, ESRD, SLE and MS (Table 2 ). We only conducted the age-specific HZ IR in IC population as stated in the study protocol and study primary objective. Discussion 271-this may be true overall but as you have not shown the calendar time analysis for each IC group, this may not be true for each group. There are many confounders such as the development of new medication regimes over the study period which may influence It is possible that the age-specific IR of HZ of different IC groups over the years would have different pattern than the stable pattern presented in the overall IC cohort. We did not run the age-specific IR of HZ for each IC condition. We added your observation to the study limitation (line 381-385).
279-the inclusion of pain medication as the case definition for PHN generally increases specificity and decreases sensitivity-therefore one would expect the rates to be lower in the studies you cite.
We rephrased that paragraph and compared the proportion of PHN within 90 days in our study to its rate in patients with HM and SM 90 days after HZ onset as presented in Habel et al., 2013 that shows lower proportion of PHN in MH and SM patients compared to our study (Habel et al., 2013) within 90 days . On the other hand, a study by Forbes et al, 2016 shows that the prevalence of PHN among IC population ranged from 7.5% in inflammatory bowel disease patients up to 29.4% in HSCT patients (Forbes et al, 2016) . (page 22, 314-these risk factors with low OR need to interpreted with extreme caution. The diagnosed chronic conditions may indicate increased physician visits and care-seeking. PHN is a notoriously bias-prone administrative-record diagnosis and may be sensitive to these factors. I suggest doing a sensitivity analysis to frequency of physician visits and control for them if you think this factor could introduce bias. We agree with your comment that chronic diseases are markers for the likely increased physician visits and healthcare-seeking behavior. We updated the study limitation to include the risk of bias in the model by not controlling for the potential increase in diagnosis of HZ by GPs due to the increased number of physician visits by patients with chronic diseases in the IC population. We will not be able to conduct the sensitivity analysis as suggested but as mentioned we added your concern to the study limitation (Page 25, .
In addition, we found that Forbes et al, 2016 ran a sensitivity analysis of the frequency of GPs visits because of chronic disease among the selected IC cohort and compared it to the average number of visits conducted by patients with epilepsy in the CPRD database. They calculated the mean yearly consultation rate prior to index date of HZ (by dividing the total number of face-to-face or telephone consultations during follow-up, by the total years of follow-up prior to index date) among patients with chronic disease included in the study. They compared this to the mean consultation rate for epilepsy, to assess whether epilepsy patients had a similar likelihood of being diagnosed with zoster. They found that consultation rates among patients with selected chronic diseases were very similar. The mean number of consultations per year among epilepsy patients was 10.2, suggesting these patients consult with similar frequency as patients included in their study of patients with chronic diseases.
329-334-This point is very difficult to follow. I suggest re-writing for clarity. The paragraph was rephrased for clarity (Line 366-368).
335-338-I suggest expanding this section to discuss the time-variability of many of the IC conditions (eg. CORT) which was only crudely accounted for in your analysis. We do agree with the reviewer that time-varying adjustment for IC conditions that evolve in severity or impact on the IC over time, however this time-varying analyses is beyond the study objectives and results as presented here. So, we put forward the research question as a possibility for future research to explore the temporal relationship between the time of HZ incident and the level of severity of immunosuppression (mild, severe) associated with IC time-varying determinants. 350-352-very vague concluding sentence. Obviously, the most important new preventive tool on the horizon is the recombinant vaccine-I suggest you conclude with implications for vaccination. The conclusion paragraph was rephrased Reviewer: 3 Reviewer Name: Ekram Wassim Institution and Country: High Institute of Public Health, Alexandria University, Egypt Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below the manuscript "The burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012" is an important topic and the results are interesting to communicate. the paper is well written and the results are properly displayed. I suggest the following points 1-to add the AOR and the P values to the tables Regarding the statistical comparison of IC to IC-free population; the study aim and design, as stated in the protocol (approved by the CPRD review committee ISAC) is a descriptive study without the intent to formally compare the IC populations to IC-free population. WE did not develop a hypothesis to compare the 2 groups at the time of developing the study protocol. In addition, we wanted to characterize the HZ and its complications in a wide range of IC conditions in CPRD with the potential heterogeneity of IC populations that would not allow us to have a robust statistical comparison between IC specific groups because of the limited number of IC individuals in the health care records of the GPs and hospital discharge summaries.
2-to derive a risk assessment model that predicts the complications in these cohort We presented the results of logistic regression model to identify the PHN risk factors since PHN is the most common HZ complications. We have similar models for other HZ complications but the identified risk factors were more or less the same as the ones identified in PHN model although the numbers of patients included in these models were limited especially after stratifying them by the risk factors (data not shown in the study).
Reviewer: 4 Reviewer Name: Obaromi Davies Institution and Country: Department of Statistics, University of Fort Hare, Alice, Eastern Cape Province, South Africa. Please state any competing interests or state 'None declared': None Declared Please leave your comments for the authors below On the strengths of the paper, the major strength was not clearly outlined, as it concerns its advantage over previous studies, either in the area of new or better methodologies and so on, That this study covered more populations than previous studies is not strong enough reason. Also, the limitation of the study is too shallow, not explicit enough. We addressed many elements in the section regarding study strengths as described in the paper (page 24 Line 355-365):
The main strength of this study was the use of a large medical records database considered to be broadly representative of the UK population.17 The linkage with HES data is only available for participants in England, but it has been reported that there are no substantial differences in participant characteristics between those that are linked to HES and those that are not.42 Therefore, over a 12+ year study period, the use of CPRD with HES linkage allowed accurate and powerful estimation of HZ incidence rates. In addition, the incidence of HZ in the IC-free cohort was slightly higher than incidence of HZ observed in the UK general population (including both immunocompetent and IC people).31,47,48
We also updated the limitation section based on reviewers' comments (page 25, Line 370-385).
